Stiripentol
Small molecule
Evidence outlook
Approved: Epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathies
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also in development:Primary Hyperoxaluria Type 1 · Phase 3 · investigational in the US
Also approved (1)
- Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STILIQ NCT07176832 · Dravet Syndrome, Epilepsy, Childhood, Epileptic Encephalopathy, Pediatric Epilepsy This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo. Registry: NCT07176832 | 1 | Relative bioavailability of stiripentol oral suspension (50 mg/mL) vs capsule (500 mg) after a single 1,000 mg oral dose with food, assessed by PK parameters Cmax, AUC0-t, and AUC0-∞ using plasma LC-MS. (Up to 36 hours post-dose (per period)) 2025-08-27 | Results not posted; external-source review pending | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other GABA-A receptor drugs
Clobazam (Onfi), Diazepam (Diastat), Diazepam (Valium), Diazepam (Valtoco), Ganaxolone and 9 more. Compare all 15 GABA-A receptor drugs
This mechanism is crowded: 14 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Stiripentol: this drug | Approved | Small molecule | GABA-A receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | Reliable signal | NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) | |
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | Reliable signal | NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100) | |
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | not yet graded | No reviewed efficacy summary in this indication | |
| Fenfluramine (Fintepla) | Approved | Small molecule | Serotonin 5-HT2 receptors | Reliable signal | NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001). NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966) | |
| Ganaxolone | Approved | Small molecule | GABA-A receptor | Partial signal | NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). | |
| Rufinamide | Approved | Small molecule | Voltage-gated sodium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Vigabatrin (Sabril) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| Vigabatrin (Vigafyde) | Approved | Small molecule | GABA transaminase (GABA-T) | not yet graded | No reviewed efficacy summary in this indication | |
| KH607 | Phase 3(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Relutrigine | Phase 3 | Small molecule | Voltage-gated sodium channel (persistent current) | not yet graded | No reviewed efficacy summary in this indication | |
| BMB-101 | Phase 2 | Small molecule | Serotonin 5-HT2C receptor (biased agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| GlyphAllo (allopregnanolone Prodrug) (SPT-300) | Phase 2(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| HS-10353 | Phase 2(overall) | Small molecule | GABA-A receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Remimazolam | Phase 1(overall) | Small molecule | GABA-A receptor | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Stiripentol to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.